Literature DB >> 32953600

Synergic effects of histology subtype, lymph node metastasis, and distant metastasis on prognosis in differentiated thyroid carcinoma using the SEER database.

Ling Zhou1, Qianqian Li1, Sichao Chen1, Yihui Huang1, Wei Wei2, Chao Zhang3, Min Wang1, Wei Zhou1, Wen Zeng4, Zeming Liu1, Liang Guo1.   

Abstract

BACKGROUND: Differentiated thyroid carcinoma (DTC) is the most common clinical type of thyroid carcinoma. There are rare reports on the synergic effects of the different clinicopathological risk factors on the prognosis of it.
METHODS: We retrospectively reviewed data on 86,032 DTC patients from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox regression analyses were conducted to evaluate the correlation between clinicopathological factors and the prognosis of DTC. Relative excess risk (RERI) of synergic effect, attributable proportion (AP) of synergic effect, and synergy index (SI) were calculated to assess synergic effects. Kaplan-Meier analyses with log-rank tests was used to plot the survival curve affected by different risk factors.
RESULTS: Histology subtype, lymph node metastasis (LNM) status, and distant metastasis (DM) were independent risk factors for cancer-specific survival (CSS) and all-cause survival (ACS) in the multivariate analysis (all, P<0.001). Patients' age at diagnosis, sex, extrathyroidal extension, and radiation also influenced prognosis (all, P<0.001). The cancer-specific mortality (CSM) and all-cause mortality (ACM) rates per 1,000 person-years were higher in patients with follicular thyroid carcinoma (FTC) and in those with N1 stage and M1 stage disease. Furthermore, we observed a significant synergic effect between histology subtype and N stage, as well as histology subtype and M stage for the CSM of DTC (RERI =48.806, AP =0.853, SI =7.565; RERI =37.889, AP =0.430, SI =1.771, respectively). However, no synergic effect was observed in the case of the N stage and M stage for the CSM of DTC (RERI =7.928, AP =0.084, SI =1.093).
CONCLUSIONS: Patients with histology subtype of FTC and N1 stage, histology subtype of FTC and M1 stage had significant additive synergic effects on DTC prognosis for CSM. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Differentiated thyroid carcinoma (DTC); Surveillance, Epidemiology, and End Results (SEER); prognosis; synergic effect

Year:  2020        PMID: 32953600      PMCID: PMC7475367          DOI: 10.21037/gs-20-273

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  31 in total

1.  Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.

Authors:  M Schlumberger; C Challeton; F De Vathaire; J P Travagli; P Gardet; J D Lumbroso; C Francese; F Fontaine; M Ricard; C Parmentier
Journal:  J Nucl Med       Date:  1996-04       Impact factor: 10.057

Review 2.  The changing incidence of thyroid cancer.

Authors:  Cari M Kitahara; Julie A Sosa
Journal:  Nat Rev Endocrinol       Date:  2016-07-15       Impact factor: 43.330

3.  An expanded view of risk-group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

4.  The Impact of Subclinical Disease and Mechanism of Detection on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Olmsted County, Minnesota During 1935 Through 2012.

Authors:  Juan P Brito; Alaa Al Nofal; Victor M Montori; Ian D Hay; John C Morris
Journal:  Thyroid       Date:  2015-07-30       Impact factor: 6.568

5.  The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.

Authors:  Fei Wang; Xiaolong Yu; Xiaopei Shen; Guangwu Zhu; Yueye Huang; Rengyun Liu; David Viola; Rossella Elisei; Efisio Puxeddu; Laura Fugazzola; Carla Colombo; Barbara Jarzab; Agnieszka Czarniecka; Alfred K Lam; Caterina Mian; Federica Vianello; Linwah Yip; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Bela Bendlova; Vlasta Sýkorová; Yangang Wang; Shiguo Liu; Jiajun Zhao; Shihua Zhao; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

Review 6.  Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.

Authors:  David Viola; Laura Valerio; Eleonora Molinaro; Laura Agate; Valeria Bottici; Agnese Biagini; Loredana Lorusso; Virginia Cappagli; Letizia Pieruzzi; Carlotta Giani; Elena Sabini; Paolo Passannati; Luciana Puleo; Antonio Matrone; Benedetta Pontillo-Contillo; Valentina Battaglia; Salvatore Mazzeo; Paolo Vitti; Rossella Elisei
Journal:  Endocr Relat Cancer       Date:  2016-04       Impact factor: 5.678

7.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.

Authors:  I D Hay; E J Bergstralh; J R Goellner; J R Ebersold; C S Grant
Journal:  Surgery       Date:  1993-12       Impact factor: 3.982

8.  Outcomes of patients with bone metastases from differentiated thyroid cancer.

Authors:  Inés Califano; Susana Deutsch; Alicia Löwenstein; Carmen Cabezón; Fabián Pitoia
Journal:  Arch Endocrinol Metab       Date:  2018-02       Impact factor: 2.309

Review 9.  Metastasis: from dissemination to organ-specific colonization.

Authors:  Don X Nguyen; Paula D Bos; Joan Massagué
Journal:  Nat Rev Cancer       Date:  2009-04       Impact factor: 60.716

10.  Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.

Authors:  Brian Hung-Hin Lang; Kai Pun Wong; Chung Yeung Cheung; Koon Yat Wan; Chung-Yau Lo
Journal:  Ann Surg Oncol       Date:  2012-10-28       Impact factor: 5.344

View more
  3 in total

1.  Bone metastases in newly diagnosed patients with thyroid cancer: A large population-based cohort study.

Authors:  Ruiguo Zhang; Wenxin Zhang; Cailan Wu; Qiang Jia; Jinyan Chai; Zhaowei Meng; Wei Zheng; Jian Tan
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

2.  A Predictive Model for the 10-year Overall Survival Status of Patients With Distant Metastases From Differentiated Thyroid Cancer Using XGBoost Algorithm-A Population-Based Analysis.

Authors:  Shuai Jin; Xing Yang; Quliang Zhong; Xiangmei Liu; Tao Zheng; Lingyan Zhu; Jingyuan Yang
Journal:  Front Genet       Date:  2022-07-08       Impact factor: 4.772

3.  BRAF p.V600E genetic testing based on ultrasound-guided fine-needle biopsy improves the malignancy rate in thyroid surgery: our single-center experience in the past 10 years.

Authors:  Lei Gong; Yan Liu; Xinghong Guo; Chuan Wang; Fei Yan; Jinbo Liu; Xinguo Hou; Li Chen; Kai Liang
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-07       Impact factor: 4.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.